ZURA BIO LIMITED Financial Liabilities Fair Value Disclosure
ZURA BIO LIMITED (ZURA) had Financial Liabilities Fair Value Disclosure of $990.00 thousand as of 2023-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:FinancialLiabilitiesFairValueDisclosure · last filed 2025-03-25
- 2023-12-31: Financial Liabilities Fair Value Disclosure $990.00K.
- 2022-12-31: Financial Liabilities Fair Value Disclosure $10.39M.
| Period end | Financial Liabilities Fair Value Disclosure |
|---|---|
| 2023-12-31 | $990.00K 10-K · filed 2025-03-25 |
| 2022-12-31 | $10.39M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |